JP2003533541A - ２−アミノ−３−ヒドロキシ−４−ｔｅｒｔ−ロイシル−アミノ−５−フェニル−ペンタン酸アミド誘導体 - Google Patents
２−アミノ−３−ヒドロキシ−４−ｔｅｒｔ−ロイシル−アミノ−５−フェニル−ペンタン酸アミド誘導体Info
- Publication number
- JP2003533541A JP2003533541A JP2001585538A JP2001585538A JP2003533541A JP 2003533541 A JP2003533541 A JP 2003533541A JP 2001585538 A JP2001585538 A JP 2001585538A JP 2001585538 A JP2001585538 A JP 2001585538A JP 2003533541 A JP2003533541 A JP 2003533541A
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- methoxy
- lower alkyl
- benzyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GDCNWEJCGIGPPQ-HRDQMINSSA-N (6S)-2,2,6-triamino-4-benzyl-3-hydroxy-7,7-dimethyl-5-oxooctanamide Chemical class CC(C)(C)[C@H](N)C(=O)C(C(O)C(N)(N)C(N)=O)CC1=CC=CC=C1 GDCNWEJCGIGPPQ-HRDQMINSSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 158
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 5
- -1 aromatic-aliphatic Chemical group 0.000 claims description 140
- 125000000217 alkyl group Chemical group 0.000 claims description 100
- 229910052757 nitrogen Inorganic materials 0.000 claims description 55
- 125000004432 carbon atom Chemical group C* 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 45
- 206010028980 Neoplasm Diseases 0.000 claims description 42
- 125000001931 aliphatic group Chemical group 0.000 claims description 34
- 150000002431 hydrogen Chemical class 0.000 claims description 33
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 28
- 229910052760 oxygen Inorganic materials 0.000 claims description 28
- 239000001301 oxygen Chemical group 0.000 claims description 28
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 28
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 25
- 125000004414 alkyl thio group Chemical class 0.000 claims description 24
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 24
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 22
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 22
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 22
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims description 22
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims description 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 19
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 19
- 125000001589 carboacyl group Chemical group 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 125000006239 protecting group Chemical group 0.000 claims description 18
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 18
- YFCDKSCUZCBUJQ-LBPRGKRZSA-N (2s)-2-amino-n-[(2-hydroxy-4-methoxyphenyl)methyl]-3-methylbutanamide Chemical compound COC1=CC=C(CNC(=O)[C@@H](N)C(C)C)C(O)=C1 YFCDKSCUZCBUJQ-LBPRGKRZSA-N 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 17
- 125000002950 monocyclic group Chemical group 0.000 claims description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000005118 N-alkylcarbamoyl group Chemical class 0.000 claims description 14
- 125000003282 alkyl amino group Chemical group 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 125000000020 sulfo group Chemical class O=S(=O)([*])O[H] 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 230000002062 proliferating effect Effects 0.000 claims description 11
- 229910052717 sulfur Chemical group 0.000 claims description 11
- 239000011593 sulfur Chemical group 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- 125000000524 functional group Chemical group 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 125000004423 acyloxy group Chemical group 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000005936 piperidyl group Chemical group 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000005493 quinolyl group Chemical group 0.000 claims description 6
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 125000002723 alicyclic group Chemical group 0.000 claims description 4
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims description 4
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000003254 radicals Chemical class 0.000 claims description 3
- PTVBXXOOKHBSMR-OOJKEJCUSA-N (2r,3r,4s)-4-[[(2s)-3,3-dimethyl-2-[(2-naphthalen-1-ylacetyl)amino]butanoyl]amino]-3-hydroxy-2-(naphthalen-1-ylmethylamino)-5-phenylpentanoic acid Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)CC=1C2=CC=CC=C2C=CC=1)C(C)(C)C)[C@@H](O)[C@@H](NCC=1C2=CC=CC=C2C=CC=1)C(O)=O)C1=CC=CC=C1 PTVBXXOOKHBSMR-OOJKEJCUSA-N 0.000 claims description 2
- QDKMUWAUVPMBMF-KHQRGBKLSA-N (2r,3r,4s)-4-[[(2s)-3,3-dimethyl-2-[(2-naphthalen-1-ylacetyl)amino]butanoyl]amino]-3-hydroxy-5-phenyl-2-[(2,3,4-trimethoxyphenyl)methylamino]pentanoic acid Chemical compound COC1=C(OC)C(OC)=CC=C1CN[C@@H](C(O)=O)[C@H](O)[C@@H](NC(=O)[C@@H](NC(=O)CC=1C2=CC=CC=C2C=CC=1)C(C)(C)C)CC1=CC=CC=C1 QDKMUWAUVPMBMF-KHQRGBKLSA-N 0.000 claims description 2
- DTMIVCFTZKWUCT-RHHFKYMDSA-N (2r,3r,4s)-4-[[(2s)-3,3-dimethyl-2-[(2-naphthalen-1-ylacetyl)amino]butanoyl]amino]-3-hydroxy-5-phenyl-2-[(2,4,5-trimethoxyphenyl)methylamino]pentanoic acid Chemical compound COC1=CC(OC)=C(OC)C=C1CN[C@@H](C(O)=O)[C@H](O)[C@@H](NC(=O)[C@@H](NC(=O)CC=1C2=CC=CC=C2C=CC=1)C(C)(C)C)CC1=CC=CC=C1 DTMIVCFTZKWUCT-RHHFKYMDSA-N 0.000 claims description 2
- QGTBFDVWPPMKSZ-NQQZCUSYSA-N (2r,3r,4s)-4-[[(2s)-3,3-dimethyl-2-[(2-naphthalen-1-ylacetyl)amino]butanoyl]amino]-3-hydroxy-5-phenyl-2-[(3,4,5-trimethoxyphenyl)methylamino]pentanoic acid Chemical compound COC1=C(OC)C(OC)=CC(CN[C@H]([C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](NC(=O)CC=2C3=CC=CC=C3C=CC=2)C(C)(C)C)C(O)=O)=C1 QGTBFDVWPPMKSZ-NQQZCUSYSA-N 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
- 125000004354 sulfur functional group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 45
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 38
- 235000002639 sodium chloride Nutrition 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 27
- 238000012360 testing method Methods 0.000 description 23
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 18
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 13
- 239000000835 fiber Substances 0.000 description 13
- 239000002994 raw material Substances 0.000 description 13
- 239000007858 starting material Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000012267 brine Substances 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000012894 fetal calf serum Substances 0.000 description 8
- 239000004530 micro-emulsion Substances 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000012510 hollow fiber Substances 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 7
- IMMRMPAXYUIDLR-UHFFFAOYSA-N (R)-3-Hydroxy-5-phenylpentanoic acid Chemical compound OC(=O)CC(O)CCC1=CC=CC=C1 IMMRMPAXYUIDLR-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 229960002743 glutamine Drugs 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011894 semi-preparative HPLC Methods 0.000 description 6
- NSVNKQLSGGKNKB-LLVKDONJSA-N (2s)-3,3-dimethyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)(C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 NSVNKQLSGGKNKB-LLVKDONJSA-N 0.000 description 5
- PRPINYUDVPFIRX-UHFFFAOYSA-N 1-naphthaleneacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 description 5
- 239000005971 1-naphthylacetic acid Substances 0.000 description 5
- 241000208199 Buxus sempervirens Species 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 235000004554 glutamine Nutrition 0.000 description 5
- 125000001624 naphthyl group Chemical group 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- LRFZIPCTFBPFLX-SSDOTTSWSA-N (2s)-3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)C(C)(C)C LRFZIPCTFBPFLX-SSDOTTSWSA-N 0.000 description 4
- ICMAFTSLXCXHRK-UHFFFAOYSA-N Ethyl pentanoate Chemical compound CCCCC(=O)OCC ICMAFTSLXCXHRK-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000037012 chymotrypsin-like activity Effects 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102000007327 Protamines Human genes 0.000 description 3
- 108010007568 Protamines Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229950008679 protamine sulfate Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- STQCJRIMCCETJZ-KSEOMHKRSA-N (2r,3r,4s)-2-[(2,4-dimethoxyphenyl)methylamino]-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenylpentanoic acid Chemical compound COC1=CC(OC)=CC=C1CN[C@@H](C(O)=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 STQCJRIMCCETJZ-KSEOMHKRSA-N 0.000 description 2
- NAFOKSZMQJOUAX-OQOFHLOUSA-N (2r,3r,4s)-4-amino-2-[[4-(dimethylamino)phenyl]methylamino]-3-hydroxy-n-[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]-5-phenylpentanamide Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@@H](N)CC=1C=CC=CC=1)NCC1=CC=C(N(C)C)C=C1 NAFOKSZMQJOUAX-OQOFHLOUSA-N 0.000 description 2
- HFETZZWHFKWVRY-OCFVUHCMSA-N (2r,3r,4s)-4-amino-3-hydroxy-n-[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]-2-(naphthalen-1-ylmethylamino)-5-phenylpentanamide Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@@H](N)CC=1C=CC=CC=1)NCC1=CC=CC2=CC=CC=C12 HFETZZWHFKWVRY-OCFVUHCMSA-N 0.000 description 2
- FBMFFJDOZKBUBP-SPJMRJSYSA-N (2r,3r,4s)-4-amino-3-hydroxy-n-[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]-5-phenyl-2-[(2,4,5-trimethoxyphenyl)methylamino]pentanamide Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@@H](N)CC=1C=CC=CC=1)NCC1=CC(OC)=C(OC)C=C1OC FBMFFJDOZKBUBP-SPJMRJSYSA-N 0.000 description 2
- LOPZGWOJLNQJND-HNEFVXLSSA-N (2r,3r,4s)-4-amino-3-hydroxy-n-[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]-5-phenyl-2-[(3,4,5-trimethoxyphenyl)methylamino]pentanamide Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@@H](N)CC=1C=CC=CC=1)NCC1=CC(OC)=C(OC)C(OC)=C1 LOPZGWOJLNQJND-HNEFVXLSSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- BYHDDXPKOZIZRV-UHFFFAOYSA-N 5-phenylpentanoic acid Chemical compound OC(=O)CCCCC1=CC=CC=C1 BYHDDXPKOZIZRV-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- TUWVWSRWURWCOR-RBZQAINGSA-N ethyl (2r,3r,4s)-2-[[4-(dimethylamino)phenyl]methylamino]-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenylpentanoate Chemical compound N([C@@H](C(=O)OCC)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)CC1=CC=C(N(C)C)C=C1 TUWVWSRWURWCOR-RBZQAINGSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229940086542 triethylamine Drugs 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- QWZMCOACPDTUIO-UHFFFAOYSA-N (2,3,4-trimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1OC QWZMCOACPDTUIO-UHFFFAOYSA-N 0.000 description 1
- CXFDSHYASCMRFH-UHFFFAOYSA-N (2,4,5-trimethoxyphenyl)methanamine Chemical compound COC1=CC(OC)=C(OC)C=C1CN CXFDSHYASCMRFH-UHFFFAOYSA-N 0.000 description 1
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KDIWDCSQLFQETL-VLCRHTCISA-N (2r,3r,4s)-2-[(3,4-dimethoxyphenyl)methylamino]-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenylpentanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CN[C@@H](C(O)=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 KDIWDCSQLFQETL-VLCRHTCISA-N 0.000 description 1
- MGXKZDUJGHWCCF-PWRODBHTSA-N (2r,3r,4s)-3-hydroxy-2-[(3-methoxyphenyl)methylamino]-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenylpentanoic acid Chemical compound COC1=CC=CC(CN[C@H]([C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OC(C)(C)C)C(O)=O)=C1 MGXKZDUJGHWCCF-PWRODBHTSA-N 0.000 description 1
- FEWNHAKFZOOCOX-RBZQAINGSA-N (2r,3r,4s)-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]-2-(naphthalen-1-ylmethylamino)-5-phenylpentanoic acid Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@@H](O)[C@@H](NCC=1C2=CC=CC=C2C=CC=1)C(O)=O)C1=CC=CC=C1 FEWNHAKFZOOCOX-RBZQAINGSA-N 0.000 description 1
- VWMZWQSAIZMMDJ-CEWLAPEOSA-N (2r,3r,4s)-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenyl-2-[(2,3,4-trimethoxyphenyl)methylamino]pentanoic acid Chemical compound COC1=C(OC)C(OC)=CC=C1CN[C@@H](C(O)=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 VWMZWQSAIZMMDJ-CEWLAPEOSA-N 0.000 description 1
- VUYUQLQHYOGBBM-CDNPAEQRSA-N (2r,3r,4s)-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenyl-2-[(2,4,5-trimethoxyphenyl)methylamino]pentanoic acid Chemical compound COC1=CC(OC)=C(OC)C=C1CN[C@@H](C(O)=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 VUYUQLQHYOGBBM-CDNPAEQRSA-N 0.000 description 1
- RQGORAUXGUEPFO-VLCRHTCISA-N (2r,3r,4s)-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenyl-2-[(3,4,5-trimethoxyphenyl)methylamino]pentanoic acid Chemical compound COC1=C(OC)C(OC)=CC(CN[C@H]([C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OC(C)(C)C)C(O)=O)=C1 RQGORAUXGUEPFO-VLCRHTCISA-N 0.000 description 1
- WUTVFMUVZCNCPP-WBADGQHESA-N (2r,3r,4s)-4-[[(2s)-2-amino-3,3-dimethylbutanoyl]amino]-2-[[4-(dimethylamino)phenyl]methylamino]-3-hydroxy-5-phenylpentanoic acid Chemical compound C1=CC(N(C)C)=CC=C1CN[C@@H](C(O)=O)[C@H](O)[C@@H](NC(=O)[C@@H](N)C(C)(C)C)CC1=CC=CC=C1 WUTVFMUVZCNCPP-WBADGQHESA-N 0.000 description 1
- PLJUJLFAFRDLND-RPLOAYLJSA-N (2r,3r,4s)-4-[[(2s)-2-amino-3,3-dimethylbutanoyl]amino]-3-hydroxy-5-phenyl-2-[(2,3,4-trimethoxyphenyl)methylamino]pentanoic acid Chemical compound COC1=C(OC)C(OC)=CC=C1CN[C@@H](C(O)=O)[C@H](O)[C@@H](NC(=O)[C@@H](N)C(C)(C)C)CC1=CC=CC=C1 PLJUJLFAFRDLND-RPLOAYLJSA-N 0.000 description 1
- LVSCUQCBJNQXNL-QXAKKESOSA-N (2r,3r,4s)-4-amino-2-[(2,4-dimethoxyphenyl)methylamino]-3-hydroxy-5-phenylpentanoic acid Chemical compound COC1=CC(OC)=CC=C1CN[C@@H](C(O)=O)[C@H](O)[C@@H](N)CC1=CC=CC=C1 LVSCUQCBJNQXNL-QXAKKESOSA-N 0.000 description 1
- HFGUXAQTFASENX-WZFJQBBKSA-N (2r,3r,4s)-4-amino-2-[(2,4-dimethoxyphenyl)methylamino]-3-hydroxy-n-[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]-5-phenylpentanamide Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@@H](N)CC=1C=CC=CC=1)NCC1=CC=C(OC)C=C1OC HFGUXAQTFASENX-WZFJQBBKSA-N 0.000 description 1
- MROHMFRUNNSIAJ-KFKAGJAMSA-N (2r,3r,4s)-4-amino-2-[(3,4-dimethoxyphenyl)methylamino]-3-hydroxy-5-phenylpentanoic acid Chemical compound C1=C(OC)C(OC)=CC=C1CN[C@@H](C(O)=O)[C@H](O)[C@@H](N)CC1=CC=CC=C1 MROHMFRUNNSIAJ-KFKAGJAMSA-N 0.000 description 1
- CKSUOMRZCDHXEN-HNEFVXLSSA-N (2r,3r,4s)-4-amino-2-[(3,4-dimethoxyphenyl)methylamino]-3-hydroxy-n-[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]-5-phenylpentanamide Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@@H](N)CC=1C=CC=CC=1)NCC1=CC=C(OC)C(OC)=C1 CKSUOMRZCDHXEN-HNEFVXLSSA-N 0.000 description 1
- UPCRHCQCCQRERB-IPMKNSEASA-N (2r,3r,4s)-4-amino-2-[(3,5-dimethoxyphenyl)methylamino]-3-hydroxy-5-phenylpentanoic acid Chemical compound COC1=CC(OC)=CC(CN[C@H]([C@H](O)[C@@H](N)CC=2C=CC=CC=2)C(O)=O)=C1 UPCRHCQCCQRERB-IPMKNSEASA-N 0.000 description 1
- QXIMFTIVWPQDKT-OQOFHLOUSA-N (2r,3r,4s)-4-amino-2-[(3,5-dimethoxyphenyl)methylamino]-3-hydroxy-n-[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]-5-phenylpentanamide Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@@H](N)CC=1C=CC=CC=1)NCC1=CC(OC)=CC(OC)=C1 QXIMFTIVWPQDKT-OQOFHLOUSA-N 0.000 description 1
- ZXJUHQNDVFMWNH-RCCFBDPRSA-N (2r,3r,4s)-4-amino-3-hydroxy-2-[(3-methoxyphenyl)methylamino]-5-phenylpentanoic acid Chemical compound COC1=CC=CC(CN[C@H]([C@H](O)[C@@H](N)CC=2C=CC=CC=2)C(O)=O)=C1 ZXJUHQNDVFMWNH-RCCFBDPRSA-N 0.000 description 1
- AVFPMZJMLUQFAA-RCCFBDPRSA-N (2r,3r,4s)-4-amino-3-hydroxy-2-[(4-methoxyphenyl)methylamino]-5-phenylpentanoic acid Chemical compound C1=CC(OC)=CC=C1CN[C@@H](C(O)=O)[C@H](O)[C@@H](N)CC1=CC=CC=C1 AVFPMZJMLUQFAA-RCCFBDPRSA-N 0.000 description 1
- MTSRGQDPIRNKOG-CWFSZBLJSA-N (2r,3r,4s)-4-amino-3-hydroxy-5-phenyl-2-[(2,4,5-trimethoxyphenyl)methylamino]pentanoic acid Chemical compound COC1=CC(OC)=C(OC)C=C1CN[C@@H](C(O)=O)[C@H](O)[C@@H](N)CC1=CC=CC=C1 MTSRGQDPIRNKOG-CWFSZBLJSA-N 0.000 description 1
- IINXZGPBKVFDRJ-KFKAGJAMSA-N (2r,3r,4s)-4-amino-3-hydroxy-5-phenyl-2-[(3,4,5-trimethoxyphenyl)methylamino]pentanoic acid Chemical compound COC1=C(OC)C(OC)=CC(CN[C@H]([C@H](O)[C@@H](N)CC=2C=CC=CC=2)C(O)=O)=C1 IINXZGPBKVFDRJ-KFKAGJAMSA-N 0.000 description 1
- LIUHOANMLRIRQR-ZYVKACNBSA-N (2r,3r,4s)-4-amino-3-hydroxy-n-[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]-2-[(3-methoxyphenyl)methylamino]-5-phenylpentanamide Chemical compound COC1=CC=CC(CN[C@H]([C@H](O)[C@@H](N)CC=2C=CC=CC=2)C(=O)N[C@@H](C(C)C)C(=O)NCC=2C(=CC(OC)=CC=2)O)=C1 LIUHOANMLRIRQR-ZYVKACNBSA-N 0.000 description 1
- DVILNDNZLPZBEU-CNTBMXMRSA-N (2r,3r,4s)-4-amino-3-hydroxy-n-[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]-5-phenyl-2-[(2,3,4-trimethoxyphenyl)methylamino]pentanamide Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@@H](N)CC=1C=CC=CC=1)NCC1=CC=C(OC)C(OC)=C1OC DVILNDNZLPZBEU-CNTBMXMRSA-N 0.000 description 1
- VWMZWQSAIZMMDJ-TYPHKJRUSA-N (2r,3s,4s)-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenyl-2-[(2,3,4-trimethoxyphenyl)methylamino]pentanoic acid Chemical compound COC1=C(OC)C(OC)=CC=C1CN[C@@H](C(O)=O)[C@@H](O)[C@@H](NC(=O)OC(C)(C)C)CC1=CC=CC=C1 VWMZWQSAIZMMDJ-TYPHKJRUSA-N 0.000 description 1
- PIYRCJFSBXGXAP-MAWMJFERSA-N (2s)-2-amino-n-[(2s,3r,4r)-3-hydroxy-5-[[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxo-1-phenyl-4-[(2,3,4-trimethoxyphenyl)methylamino]pentan-2-yl]-3,3-dimethylbutanamide Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)C(C)(C)C)NCC1=CC=C(OC)C(OC)=C1OC PIYRCJFSBXGXAP-MAWMJFERSA-N 0.000 description 1
- NQJDBWXTLCUDRM-OSNKRYAHSA-N (2s)-2-amino-n-[(2s,3r,4r)-3-hydroxy-5-[[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxo-1-phenyl-4-[(2,4,5-trimethoxyphenyl)methylamino]pentan-2-yl]-3,3-dimethylbutanamide Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)C(C)(C)C)NCC1=CC(OC)=C(OC)C=C1OC NQJDBWXTLCUDRM-OSNKRYAHSA-N 0.000 description 1
- WWVMFOMILYVJGN-ISDCAAOQSA-N (2s)-2-amino-n-[(2s,3r,4r)-3-hydroxy-5-[[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxo-1-phenyl-4-[(3,4,5-trimethoxyphenyl)methylamino]pentan-2-yl]-3,3-dimethylbutanamide Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)C(C)(C)C)NCC1=CC(OC)=C(OC)C(OC)=C1 WWVMFOMILYVJGN-ISDCAAOQSA-N 0.000 description 1
- YGVWKUSYRJCURO-BTUYWOMTSA-N (2s)-2-amino-n-[(2s,3r,4r)-4-[[4-(dimethylamino)phenyl]methylamino]-3-hydroxy-5-[[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxo-1-phenylpentan-2-yl]-3,3-dimethylbutanamide Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)C(C)(C)C)NCC1=CC=C(N(C)C)C=C1 YGVWKUSYRJCURO-BTUYWOMTSA-N 0.000 description 1
- YUPUSBMJCFBHAP-UHFFFAOYSA-N (3,4,5-trimethoxyphenyl)methanamine Chemical compound COC1=CC(CN)=CC(OC)=C1OC YUPUSBMJCFBHAP-UHFFFAOYSA-N 0.000 description 1
- DIVNUTGTTIRPQA-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1OC DIVNUTGTTIRPQA-UHFFFAOYSA-N 0.000 description 1
- YGZJTYCCONJJGZ-UHFFFAOYSA-N (3,5-dimethoxyphenyl)methanamine Chemical compound COC1=CC(CN)=CC(OC)=C1 YGZJTYCCONJJGZ-UHFFFAOYSA-N 0.000 description 1
- GRRIMVWABNHKBX-UHFFFAOYSA-N (3-methoxyphenyl)methanamine Chemical compound COC1=CC=CC(CN)=C1 GRRIMVWABNHKBX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- RXYPXQSKLGGKOL-UHFFFAOYSA-N 1,4-dimethylpiperazine Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- JZWSJKRJDWHVBS-UHFFFAOYSA-N 2-hydroxy-5-phenylpentanoic acid Chemical compound OC(=O)C(O)CCCC1=CC=CC=C1 JZWSJKRJDWHVBS-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
- 125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 101100351961 Caenorhabditis elegans pgp-1 gene Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 101000680262 Homo sapiens Transmembrane protein 60 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 238000001282 Kruskal–Wallis one-way analysis of variance Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- CXEGPBQTTDWSQO-XTZSFRBLSA-N NC1=CC=C2C(=CC(OC2=C1)=O)C.N[C@@H](CC1=CC=C(C=C1)O)C(=O)O.N[C@@H](C(C)C)C(=O)O.N[C@@H](CC(C)C)C(=O)O.C(CCC(=O)O)(=O)N[C@@H](CC(C)C)C(=O)O Chemical compound NC1=CC=C2C(=CC(OC2=C1)=O)C.N[C@@H](CC1=CC=C(C=C1)O)C(=O)O.N[C@@H](C(C)C)C(=O)O.N[C@@H](CC(C)C)C(=O)O.C(CCC(=O)O)(=O)N[C@@H](CC(C)C)C(=O)O CXEGPBQTTDWSQO-XTZSFRBLSA-N 0.000 description 1
- YQIHIQZQNXAPBI-FHZUCYEKSA-N OC1=C(CNC(=O)[C@H](C(C)C)NC(C(CCC)NCC2=C(C(=C(C=C2)OC)OC)OC)=O)C=CC(=C1)OC Chemical compound OC1=C(CNC(=O)[C@H](C(C)C)NC(C(CCC)NCC2=C(C(=C(C=C2)OC)OC)OC)=O)C=CC(=C1)OC YQIHIQZQNXAPBI-FHZUCYEKSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102100022076 Transmembrane protein 60 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- OUYSXPMAYYVRRP-OCFVUHCMSA-N [(2S,3R,4R)-3-hydroxy-5-[[(2S)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]amino]-4-(naphthalen-1-ylmethylamino)-5-oxo-1-phenylpentan-2-yl]carbamic acid Chemical compound C(C1=CC=CC=C1)[C@@H]([C@H]([C@@H](NCC1=CC=CC2=CC=CC=C12)C(N[C@@H](C(C)C)C(NCC1=C(C=C(C=C1)OC)O)=O)=O)O)NC(O)=O OUYSXPMAYYVRRP-OCFVUHCMSA-N 0.000 description 1
- FBTAJSAMZPOCFY-HNEFVXLSSA-N [(2S,3R,4R)-3-hydroxy-5-[[(2S)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxo-1-phenyl-4-[(3,4,5-trimethoxyphenyl)methylamino]pentan-2-yl]carbamic acid Chemical compound C(C1=CC=CC=C1)[C@@H]([C@H]([C@H](C(N[C@@H](C(C)C)C(NCC1=C(C=C(C=C1)OC)O)=O)=O)NCC1=CC(=C(C(=C1)OC)OC)OC)O)NC(O)=O FBTAJSAMZPOCFY-HNEFVXLSSA-N 0.000 description 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000012971 dimethylpiperazine Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- QUXRLYBWZXJEIS-QPTUXGOLSA-N ethyl (2r,3r,4s)-2-[(2,4-dimethoxyphenyl)methylamino]-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenylpentanoate Chemical compound N([C@@H](C(=O)OCC)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)CC1=CC=C(OC)C=C1OC QUXRLYBWZXJEIS-QPTUXGOLSA-N 0.000 description 1
- QYKIMCIOXCJHQE-YTFSRNRJSA-N ethyl (2r,3r,4s)-3-hydroxy-2-[(3-methoxyphenyl)methylamino]-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenylpentanoate Chemical compound N([C@@H](C(=O)OCC)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)CC1=CC=CC(OC)=C1 QYKIMCIOXCJHQE-YTFSRNRJSA-N 0.000 description 1
- QBISKBFYOHVZJK-JIMJEQGWSA-N ethyl (2r,3r,4s)-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]-2-(naphthalen-1-ylmethylamino)-5-phenylpentanoate Chemical compound C([C@@H]([C@@H](O)[C@@H](NCC=1C2=CC=CC=C2C=CC=1)C(=O)OCC)NC(=O)OC(C)(C)C)C1=CC=CC=C1 QBISKBFYOHVZJK-JIMJEQGWSA-N 0.000 description 1
- UFPCKUPLHFNYSK-MDNUFGMLSA-N ethyl (2r,3r,4s)-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenyl-2-[(2,3,4-trimethoxyphenyl)methylamino]pentanoate Chemical compound N([C@@H](C(=O)OCC)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)CC1=CC=C(OC)C(OC)=C1OC UFPCKUPLHFNYSK-MDNUFGMLSA-N 0.000 description 1
- RZSPZCSDHSCSKR-TUACAJSNSA-N ethyl (2r,3r,4s)-3-hydroxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-phenyl-2-[(3,4,5-trimethoxyphenyl)methylamino]pentanoate Chemical compound N([C@@H](C(=O)OCC)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)CC1=CC(OC)=C(OC)C(OC)=C1 RZSPZCSDHSCSKR-TUACAJSNSA-N 0.000 description 1
- QCHDRUGIAZBPGB-UHFFFAOYSA-N ethyl 5-phenylpentanoate Chemical compound CCOC(=O)CCCCC1=CC=CC=C1 QCHDRUGIAZBPGB-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000006301 indolyl methyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NVSYANRBXPURRQ-UHFFFAOYSA-N naphthalen-1-ylmethanamine Chemical compound C1=CC=C2C(CN)=CC=CC2=C1 NVSYANRBXPURRQ-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical class CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 229940000207 selenious acid Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-N selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YUVQMEZBAXUYKM-OCFVUHCMSA-N tert-butyl n-[(2s,3r,4r)-3-hydroxy-5-[[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]amino]-4-[(3-methoxyphenyl)methylamino]-5-oxo-1-phenylpentan-2-yl]carbamate Chemical compound COC1=CC=CC(CN[C@H]([C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)OC(C)(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC=2C(=CC(OC)=CC=2)O)=C1 YUVQMEZBAXUYKM-OCFVUHCMSA-N 0.000 description 1
- PSDRMCAMUYFGHU-OYUXKOKYSA-N tert-butyl n-[(2s,3r,4r)-3-hydroxy-5-[[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxo-1-phenyl-4-[(2,3,4-trimethoxyphenyl)methylamino]pentan-2-yl]carbamate Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)NCC1=CC=C(OC)C(OC)=C1OC PSDRMCAMUYFGHU-OYUXKOKYSA-N 0.000 description 1
- SWIUMQVIMNADQP-TVXNHBSRSA-N tert-butyl n-[(2s,3r,4r)-3-hydroxy-5-[[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxo-1-phenyl-4-[(2,4,5-trimethoxyphenyl)methylamino]pentan-2-yl]carbamate Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)NCC1=CC(OC)=C(OC)C=C1OC SWIUMQVIMNADQP-TVXNHBSRSA-N 0.000 description 1
- YZEONOHIXUDPBF-DLLFKZJKSA-N tert-butyl n-[(2s,3r,4r)-4-[(3,4-dimethoxyphenyl)methylamino]-3-hydroxy-5-[[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxo-1-phenylpentan-2-yl]carbamate Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)NCC1=CC=C(OC)C(OC)=C1 YZEONOHIXUDPBF-DLLFKZJKSA-N 0.000 description 1
- SUSQXZWLEDGJSD-GFOUJFQOSA-N tert-butyl n-[(2s,3r,4r)-4-[(3,5-dimethoxyphenyl)methylamino]-3-hydroxy-5-[[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxo-1-phenylpentan-2-yl]carbamate Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)NCC1=CC(OC)=CC(OC)=C1 SUSQXZWLEDGJSD-GFOUJFQOSA-N 0.000 description 1
- WNIGSMLFPNMARQ-GFOUJFQOSA-N tert-butyl n-[(2s,3r,4r)-4-[[4-(dimethylamino)phenyl]methylamino]-3-hydroxy-5-[[(2s)-1-[(2-hydroxy-4-methoxyphenyl)methylamino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxo-1-phenylpentan-2-yl]carbamate Chemical compound OC1=CC(OC)=CC=C1CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]([C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)NCC1=CC=C(N(C)C)C=C1 WNIGSMLFPNMARQ-GFOUJFQOSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000010518 undesired secondary reaction Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0012795.1 | 2000-05-25 | ||
| GBGB0012795.1A GB0012795D0 (en) | 2000-05-25 | 2000-05-25 | Organic compounds |
| PCT/EP2001/005952 WO2001089282A2 (en) | 2000-05-25 | 2001-05-23 | 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003533541A true JP2003533541A (ja) | 2003-11-11 |
| JP2003533541A5 JP2003533541A5 (enExample) | 2008-06-19 |
Family
ID=9892401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001585538A Pending JP2003533541A (ja) | 2000-05-25 | 2001-05-23 | ２−アミノ−３−ヒドロキシ−４−ｔｅｒｔ−ロイシル−アミノ−５−フェニル−ペンタン酸アミド誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20030166572A1 (enExample) |
| EP (1) | EP1290012B1 (enExample) |
| JP (1) | JP2003533541A (enExample) |
| AT (1) | ATE325809T1 (enExample) |
| AU (1) | AU2001266019A1 (enExample) |
| CA (1) | CA2405871A1 (enExample) |
| DE (1) | DE60119514T2 (enExample) |
| ES (1) | ES2261422T3 (enExample) |
| GB (1) | GB0012795D0 (enExample) |
| PT (1) | PT1290012E (enExample) |
| WO (1) | WO2001089282A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006508166A (ja) * | 2002-11-27 | 2006-03-09 | イーラン ファーマスーティカルズ、インコーポレイテッド | 置換尿素及びカルバメート |
| GB0504950D0 (en) * | 2005-03-10 | 2005-04-20 | Novartis Ag | Organic compositions |
| CA2604133C (en) | 2005-04-07 | 2015-12-01 | Centre National De La Recherche Scientifique | Compounds useful as modulators of the proteasome activity |
| EP2257281A2 (en) * | 2008-02-28 | 2010-12-08 | Novartis AG | Combination comprising a cannabinoid receptor binding compound and an opioid |
| WO2010096574A1 (en) | 2009-02-20 | 2010-08-26 | Lisanti Michael P | A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm |
| US10085987B2 (en) | 2012-01-27 | 2018-10-02 | Thomas Jefferson University | MCT protein inhibitor-related prognostic and therapeutic methods |
| EP2986290A4 (en) | 2013-04-19 | 2017-01-04 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
| CN118373875A (zh) * | 2018-05-29 | 2024-07-23 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5538997A (en) * | 1993-03-12 | 1996-07-23 | Sandoz Ltd. | 2,4-diamino-3-hydroxycarboxylic acid derivatives |
| EP0982317A1 (en) * | 1998-08-26 | 2000-03-01 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bivalent inhibitors of the proteasome |
| EP1173413B1 (en) * | 1999-04-27 | 2004-06-30 | Novartis AG | Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors |
-
2000
- 2000-05-25 GB GBGB0012795.1A patent/GB0012795D0/en not_active Ceased
-
2001
- 2001-05-23 PT PT01943442T patent/PT1290012E/pt unknown
- 2001-05-23 AT AT01943442T patent/ATE325809T1/de not_active IP Right Cessation
- 2001-05-23 AU AU2001266019A patent/AU2001266019A1/en not_active Abandoned
- 2001-05-23 JP JP2001585538A patent/JP2003533541A/ja active Pending
- 2001-05-23 US US10/258,901 patent/US20030166572A1/en not_active Abandoned
- 2001-05-23 EP EP01943442A patent/EP1290012B1/en not_active Expired - Lifetime
- 2001-05-23 WO PCT/EP2001/005952 patent/WO2001089282A2/en not_active Ceased
- 2001-05-23 DE DE60119514T patent/DE60119514T2/de not_active Expired - Fee Related
- 2001-05-23 CA CA002405871A patent/CA2405871A1/en not_active Abandoned
- 2001-05-23 ES ES01943442T patent/ES2261422T3/es not_active Expired - Lifetime
-
2006
- 2006-05-15 US US11/434,398 patent/US20060205673A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2405871A1 (en) | 2001-11-29 |
| EP1290012B1 (en) | 2006-05-10 |
| US20030166572A1 (en) | 2003-09-04 |
| PT1290012E (pt) | 2006-09-29 |
| DE60119514D1 (de) | 2006-06-14 |
| DE60119514T2 (de) | 2006-10-05 |
| AU2001266019A1 (en) | 2001-12-03 |
| US20060205673A1 (en) | 2006-09-14 |
| ATE325809T1 (de) | 2006-06-15 |
| EP1290012A2 (en) | 2003-03-12 |
| WO2001089282A2 (en) | 2001-11-29 |
| ES2261422T3 (es) | 2006-11-16 |
| WO2001089282A3 (en) | 2002-05-10 |
| GB0012795D0 (en) | 2000-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6937090B2 (ja) | 免疫調節剤としての１，２，４−オキサジアゾールおよびチアジアゾール化合物 | |
| JP4416501B2 (ja) | ２−｛［ｎ−（２−アミノ−３−（ヘテロアリールまたはアリール）プロピオニル）−アミノアシル］−アミノ｝−アルキルボロン酸誘導体 | |
| JP2020189847A (ja) | ペプチド及びペプチド関連化合物の高浸透性プロドラッグ組成物 | |
| JP3112327B2 (ja) | Ａｃｅの阻害剤として有用な新規なアミノ及びニトロ含有三環式化合物類 | |
| JPH05230095A (ja) | 治療薬としての新規５−アミノ−４−ヒドロキシヘキサン酸誘導体 | |
| SK25799A3 (en) | Heterocyclic metalloprotease inhibitors | |
| EA005740B1 (ru) | Карбаматные ингибиторы каспазы и их использование | |
| JP2001520674A (ja) | ペプチジル−２−アミノ−１−ヒドロキシアルカンスルホン酸システインプロテアーゼインヒビター | |
| CN100357267C (zh) | 2,4－二氨基－3－羟基羧酸衍生物在制备作为蛋白酶体抑制剂的药物中的用途 | |
| US20030166572A1 (en) | 2-Amino-3-hydroxy-4-tert-leucyl-amino-5 phenyl-pentanoic acid amide derivatives | |
| JP3987586B2 (ja) | ２，４−ジアミノ−３−ヒドロキシカルボン酸誘導体 | |
| JP4604161B2 (ja) | フェニルアラニン誘導体 | |
| TW200526585A (en) | Anti-inflammatory agents | |
| KR101264934B1 (ko) | 아미도메틸-치환1-(카르복시알킬)-시클로펜틸카보닐아미노-벤자제핀-ｎ-아세트산 유도체, 그것의 제조를 위한 공정 및 중간체 생성물및 이들 화합물을 포함하는 의약품 | |
| JPH06329552A (ja) | 腫瘍疾患を処置するための組成物 | |
| CN101400352B (zh) | 用于治疗和预防疾病的组合物和方法 | |
| JPH09509158A (ja) | エンケファリナーゼ及びａｃｅの阻害剤として有用な、新規なメルカプトアセチルアミドジスルフィド誘導体類 | |
| TW201443016A (zh) | 具有醯胺－內醯胺之異羥肟酸衍生物作爲有效的組蛋白脫乙醯基酶抑制劑及其醫藥用途 | |
| JPH09508417A (ja) | 抗ウイルス剤として有用なマクロ環式ジフルオロスタトン誘導体類 | |
| HK1044931B (en) | Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | |
| JPH0840886A (ja) | 長鎖の非分枝鎖状アルキルアミドおよびそれを含有する抗増殖および炎症抑制医薬品 | |
| JPH11503450A (ja) | Ｃ−末端アミネルジックな側鎖アミノ酸残基を含む血小板凝集抑制物質 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080501 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080501 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110208 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110927 |